|
18F-Fluoroestradiol (FES) and 18F-Fluorodeoxyglucose (FDG) PET imaging in lobular breast cancer. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Abbvie; Advaxis; Celgene |
Research Funding - Abbvie (Inst); Cascadian Therapeutics (Inst); Celgene (Inst); Celldex (Inst); Genentech/Roche (Inst); Juno Therapeutics (Inst); Merck (Inst); Myriad Pharmaceuticals (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - PET/X LLC |
Research Funding - GE Healthcare |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |